Business ❯Pharmaceutical Industry ❯Drug Development

Clinical Research

Drug Safety Market Competition Lykos Therapeutics Market Analysis Market Withdrawal Market Approval UCB SA Novo Nordisk

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

The experimental drug combines GLP-1 and amylin hormones, offering potential advances in obesity treatment.

Novo Nordisk's Oral Semaglutide Shows 14% Reduction in Heart Risks

Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

Roche Accelerates Development of Promising Weight-Loss Pills

FDA Faces Critical Decision on MDMA Therapy for PTSD